November 2024
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges
Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition
Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials
AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy
AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry
Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks
Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)
BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody
BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Marinus Pharmaceuticals Slashes 45% of Workforce Following Disappointing Phase 3 Trial Results
Marinus Pharmaceuticals, staff layoffs, phase 3 trials, ganaxolone, refractory status epilepticus, RAISE trial, TrustTSC trial
BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance
BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry
23andMe Restructures, Cuts 40% of Workforce and Ends Therapeutics Division Amid Financial Struggles
23andMe, layoffs, therapeutics division, financial struggles, genetic testing, data security
UnitedHealth’s Optum Defends $3.3 Billion Acquisition of Amedisys Amid DOJ Lawsuit
Optum, Amedisys, UnitedHealth, DOJ, Acquisition, Healthcare, Antitrust